Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2611-2618

  Ling, Sunbin ^a   Feng, Tingting ^a   Ke, Qinghong ^b   Fan, Ning ^a   Li, Lei ^a   Li, Zhongxing ^a   Dong, Chengyong ^a   Wang, Cong ^a   Xu, Fei ^a   Li, Yan ^a   Wang, Liming ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Chemosensitivity; Intrahepatic cholangiocarcinoma cells; Metformin; Proliferation

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FLUOROURACIL; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PROTEIN BCL 2; SORAFENIB; AMP-ACTIVATED PROTEIN KINASE KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DENSITY; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHEMOSENSITIVITY; CHOLANGIOCARCINOMA CELL LINE; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE, NEOPLASM; HUMANS; METFORMIN; MULTIPROTEIN COMPLEXES; PROTEIN KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84902207351     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3151     Document Type: Article

References (38)

1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005. (Pubitemid 40813563)
2. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
3. Dowling RJ, Niraula S, Stambolic V and Goodwin PJ: Metformin in cancer: translational challenges. J Mol Endocrinol 48: R31-R43, 2012.
4. Nair V, Pathi S, Jutooru I, et al: Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 34: 2870-2879, 2013.
5. Akinyeke T, Matsumura S, Wang X, et al: Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 34: 2823-2832, 2013.
6. Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
7. Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-560, 2012.
8. Petrushev B, Tomuleasa C, Soritau O, et al: Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol 34: 17-24, 2012.
9. Ashinuma H, Takiguchi Y, Kitazono S, et al: Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep 28: 8-14, 2012.
10. Chen G, Xu S, Renko K and Derwahl M: Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 97: E510-E520, 2012.
11. Chaiteerakij R, Yang JD, Harmsen WS, et al: Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 57: 648-655, 2013.
12. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357, 2001.
13. Tyson GL and El-Serag HB: Risk factors for cholangiocarcinoma. Hepatology 54: 173-184, 2011.
14. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005. (Pubitemid 41416587)
15. Shaib YH, Davila JA, McGlynn K and El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40: 472-477, 2004. (Pubitemid 38230849)
16. Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L and Athar M: Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 88: 1149-1156, 2012.
17. Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen F: In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 12: 517, 2012.
18. Lin B, Kolluri SK, Lin F, et al: Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116: 527-540, 2004. (Pubitemid 38264430)
19. Lee D, Do IG, Choi K, et al: The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 25: 131-139, 2012.
20. Chung JY, Hong SM, Choi BY, Cho H, Yu E and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15: 660-667, 2009.
21. Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
22. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
23. McCubrey JA, Steelman LS, Chappell WH, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3: 1068-1111, 2012.
24. McCubrey JA, Steelman LS, Chappell WH, et al: Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3: 954-987, 2012.
25. Takiyama Y, Harumi T, Watanabe J, et al: Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 60: 981-992, 2011.
26. Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan E and Oktay TM: Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it affect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev 13: 5143-5148, 2012.
27. Zannella VE, Pra AD, Muaddi H, et al: Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19: 6741-6750, 2013.
28. Sheng B, Liu J and Li GH: Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling. Comp Biochem Physiol B Biochem Mol Biol 163: 51-58, 2012.
29. Li Y and Ye D: Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets 10: 782-796, 2010.
30. Rho JK, Choi YJ, Lee JK, et al: Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1α. Oncol Rep 21: 801-807, 2009.
31. Huang C, Xu D, Xia Q, Wang P, Rong C and Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol 64: 1741-1750, 2012.
32. Zhu H, Luo SF, Wang J, et al: Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxia-inducible factor-1alpha. Chin Med J (Engl) 125: 1095-1103, 2012.
33. Ding Z, Yang L, Xie X, et al: Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707, 2010.
34. Li DW, Dong P, Wang F, Chen XW, Xu CZ and Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1alpha. Asian Pac J Cancer Prev 14: 4853-4858, 2013.
35. Chen M, Huang SL, Zhang XQ, et al: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.
36. Woo HY and Heo J: Sorafenib in liver cancer. Expert Opin Pharmacother 13: 1059-1067, 2012.
37. Eguchi R, Fujimori Y, Takeda H, et al: Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol 226: 762-768, 2011.
38. 3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells. Pharmacol Res 77: 11-21, 2013.